Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipeline Target constitutes close to 9 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22219TDB, outlays comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR). The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Dermatology, Immunology and Respiratory which include indications Triple-Negative Breast Cancer (TNBC), Actinic (Solar) Keratosis, Arrhythmias, Asthma, Cervical Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastrointestinal Tumor, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Lung Cancer, Malignant Glioma, Medulloblastoma, Myocardial Infarction, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Skin Cancer and Solid Tumor.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) – Overview
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) – Companies Involved in Therapeutics Development
Athenex Inc
Nuvectis Pharma Inc
Pulmatrix Inc
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) – Drug Profiles
KX-2361 – Drug Profile
NXP-900 – Drug Profile
PP-1 – Drug Profile
PUR-1800 – Drug Profile
Small Molecules to Inhibit C Src Kinase for Colon Cancer – Drug Profile
Small Molecules to Inhibit CSK for Oncology – Drug Profile
Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer – Drug Profile
tirbanibulin – Drug Profile
UM-164 – Drug Profile
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) – Dormant Products
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) – Discontinued Products
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) – Product Development Milestones
Featured News & Press Releases
Oct 18, 2022: Nuvectis Phrama announces poster presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
Aug 18, 2022: Almirall's Klisyri (tirbanibulin) receives strong recommendation in American Academy of Dermatology AK guideline update
Jun 22, 2022: Athenex announces sale of revenues from U.S. and European Royalty and Milestone Interests in Klisyri (tirbanibulin) to Sagard Healthcare partners and Oaktree
Apr 13, 2022: Nuvectis Pharma recaps Poster Presentation highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
Mar 21, 2022: Pulmatrix announces positive top-line data evaluating PUR1800 in Patients with Stable COPD
Mar 10, 2022: Nuvectis announces upcoming oral and poster presentations at the 2022 American Association for Cancer Research Meeting
Feb 22, 2022: Nuvectis announces positive data for NXP900 in triple negative breast cancer preclinical models with an Integrin-Linked Kinase (ILK) Loss
Sep 27, 2021: Almirall launches Klisyri(Tirbanibulin) for the treatment of actinic keratosis in Europe
Jul 19, 2021: Almirall receives European Commission approval of Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
May 21, 2021: Almirall receives positive CHMP opinion for Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
Apr 12, 2021: Pulmatrix to regain full rights to PUR1800 and narrow spectrum kinase inhibitor portfolio
Mar 04, 2021: Pulmatrix provides update on its lung cancer drug candidate PUR-1800
Feb 18, 2021: Almirall U.S. launches Klisyri (tirbanibulin), a new, innovative topical treatment for actinic keratosis
Feb 18, 2021: Athenex announces U.S. launch of Klisyri and licensing of additional territories for tirbanibulin
Feb 11, 2021: Athenex announces New England Journal of Medicine publication of phase III data on the efficacy and safety of Klisyri (tirbanibulin)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development by Stage of Development, 2022
Table 2: Number of Products under Development by Therapy Areas, 2022
Table 3: Number of Products under Development by Indication, 2022
Table 4: Number of Products under Development by Companies, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Number of Products under Investigation by Universities/Institutes, 2022
Table 8: Products under Investigation by Universities/Institutes, 2022
Table 9: Number of Products by Stage and Mechanism of Actions, 2022
Table 10: Number of Products by Stage and Route of Administration, 2022
Table 11: Number of Products by Stage and Molecule Type, 2022
Table 12: Pipeline by Athenex Inc, 2022
Table 13: Pipeline by Nuvectis Pharma Inc, 2022
Table 14: Pipeline by Pulmatrix Inc, 2022
Table 15: Dormant Products, 2022
Table 16: Dormant Products, 2022 (Contd..1)
Table 17: Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development by Stage of Development, 2022
Figure 2: Number of Products under Development by Therapy Areas, 2022
Figure 3: Number of Products under Development by Top 10 Indications, 2022
Figure 4: Number of Products by Stage and Mechanism of Actions, 2022
Figure 5: Number of Products by Routes of Administration, 2022
Figure 6: Number of Products by Stage and Routes of Administration, 2022
Figure 7: Number of Products by Molecule Types, 2022
Figure 8: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings